SPOTLIGHT: Final OS Results for Zolbetuximab Plus mFOLFOX6 in Metastatic Gastric/GEJ Adenocarcinoma

David H. Ilson, MD, PhD, of Memorial Sloan Kettering Cancer Center, and Nataliya Uboha, MD, PhD, of University of Wisconsin School of Medicine and Public Health, highlight the final OS results of the phase 3 SPOTLIGHT study.

Together, they explore the significant improvements in PFS and OS with zolbetuximab plus mFOLFOX6 as a first-line treatment for patients with CLDN18.2-positive, HER2-negative, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma, affirming its potential as a new standard of care.